Clinical trial

Phase I Study of the Combination of Anlotinib With Gefitinib

NCT03602027

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Anlotinib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gefitinib Normalized identity: gefitinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase I Study of the Combination of Anlotinib With Gefitinib

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-08-01

PhaseNA

Conditions

Non-squamous Non-small Cell Lung Cancerunresolved

Interventions

AnlotinibDRUG

GefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

Second Affiliated Hospital of Nanchang Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03602027 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.